{
    "organizations": [],
    "uuid": "f75689ec5486ef77ab24abf6bfb3c407b43f5360",
    "author": "",
    "url": "https://www.reuters.com/article/brief-ultragenyx-and-kyowa-kirin-announc/brief-ultragenyx-and-kyowa-kirin-announce-crysvita-now-launched-in-the-u-s-idUSFWN1S70Y9",
    "ord_in_thread": 0,
    "title": "BRIEF-Ultragenyx And Kyowa Kirin Announce Crysvita® (Burosumab-Twza) Now Launched In The U.S.",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30, 2018 / 12:55 PM / Updated 7 minutes ago BRIEF-Ultragenyx And Kyowa Kirin Announce Crysvita® (Burosumab-Twza) Now Launched In The U.S. Reuters Staff 1 Min Read\nApril 30 (Reuters) - Ultragenyx Pharmaceutical Inc:\n* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE CRYSVITA® (BUROSUMAB-TWZA) NOW LAUNCHED IN THE U.S. FOR THE TREATMENT OF X–LINKED HYPOPHOSPHATEMIA (XLH) IN CHILDREN AND ADULTS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)",
    "published": "2018-04-30T15:55:00.000+03:00",
    "crawled": "2018-04-30T16:12:44.014+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "kyowa",
        "kirin",
        "announce",
        "launched",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "ultragenyx",
        "pharmaceutical",
        "inc",
        "ultragenyx",
        "kyowa",
        "kirin",
        "announce",
        "launched",
        "treatment",
        "hypophosphatemia",
        "xlh",
        "child",
        "adult",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}